These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 15954490)
1. Duration of virus shedding after trivalent intranasal live attenuated influenza vaccination in adults. Talbot TR; Crocker DD; Peters J; Doersam JK; Ikizler MR; Sannella E; Wright PE; Edwards KM Infect Control Hosp Epidemiol; 2005 May; 26(5):494-500. PubMed ID: 15954490 [TBL] [Abstract][Full Text] [Related]
2. Shedding of Ann Arbor strain live attenuated influenza vaccine virus in children 6-59 months of age. Mallory RM; Yi T; Ambrose CS Vaccine; 2011 Jun; 29(26):4322-7. PubMed ID: 21513761 [TBL] [Abstract][Full Text] [Related]
3. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age. Block SL; Yogev R; Hayden FG; Ambrose CS; Zeng W; Walker RE Vaccine; 2008 Sep; 26(38):4940-6. PubMed ID: 18662737 [TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer. Carr S; Allison KJ; Van De Velde LA; Zhang K; English EY; Iverson A; Daw NC; Howard SC; Navid F; Rodriguez-Galindo C; Yang J; Adderson EE; McCullers JA; Flynn PM J Infect Dis; 2011 Nov; 204(10):1475-82. PubMed ID: 21949042 [TBL] [Abstract][Full Text] [Related]
5. Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. King JC; Treanor J; Fast PE; Wolff M; Yan L; Iacuzio D; Readmond B; O'Brien D; Mallon K; Highsmith WE; Lambert JS; Belshe RB J Infect Dis; 2000 Feb; 181(2):725-8. PubMed ID: 10669363 [TBL] [Abstract][Full Text] [Related]
6. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children. Piedra PA; Gaglani MJ; Kozinetz CA; Herschler GB; Fewlass C; Harvey D; Zimmerman N; Glezen WP Pediatrics; 2007 Sep; 120(3):e553-64. PubMed ID: 17698577 [TBL] [Abstract][Full Text] [Related]
7. Nasal shedding of vaccine viruses after immunization with a Russian-backbone live attenuated influenza vaccine in India. Dar L; Krishnan A; Kumar R; Dhakad S; Choudekar A; Bagga S; Sharma A; Kumar A; Jethani J; Saha S; Amarchand R; Kumar R; Choudhary A; Narayan VV; Gopal G; Lafond KE; Lindstrom S Influenza Other Respir Viruses; 2023 Jun; 17(6):e13149. PubMed ID: 37380175 [TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults. Block SL; Yi T; Sheldon E; Dubovsky F; Falloon J Vaccine; 2011 Nov; 29(50):9391-7. PubMed ID: 21983154 [TBL] [Abstract][Full Text] [Related]
9. The role of nasal IgA in children vaccinated with live attenuated influenza vaccine. Ambrose CS; Wu X; Jones T; Mallory RM Vaccine; 2012 Nov; 30(48):6794-801. PubMed ID: 23000125 [TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine. Vesikari T; Karvonen A; Korhonen T; Edelman K; Vainionpää R; Salmi A; Saville MK; Cho I; Razmpour A; Rappaport R; O'Neill R; Georgiu A; Gruber W; Mendelman PM; Forrest B; Pediatr Infect Dis J; 2006 Jul; 25(7):590-5. PubMed ID: 16804427 [TBL] [Abstract][Full Text] [Related]
12. Duration of the protective immune response after prime and booster vaccination of yearlings with a live modified cold-adapted viral vaccine against equine influenza. Tabynov K; Kydyrbayev Zh; Ryskeldinova Sh; Assanzhanova N; Sansyzbay A Vaccine; 2014 May; 32(25):2965-71. PubMed ID: 24726250 [TBL] [Abstract][Full Text] [Related]
14. The use of a systemic prime/mucosal boost strategy with an equine influenza ISCOM vaccine to induce protective immunity in horses. Crouch CF; Daly J; Henley W; Hannant D; Wilkins J; Francis MJ Vet Immunol Immunopathol; 2005 Dec; 108(3-4):345-55. PubMed ID: 16098611 [TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children. Block SL; Falloon J; Hirschfield JA; Krilov LR; Dubovsky F; Yi T; Belshe RB Pediatr Infect Dis J; 2012 Jul; 31(7):745-51. PubMed ID: 22466322 [TBL] [Abstract][Full Text] [Related]
16. Vaccine-specific antibody secreting cells are a robust early marker of LAIV-induced B-cell response in ferrets. Cherukuri A; Servat E; Woo J Vaccine; 2012 Jan; 30(2):237-46. PubMed ID: 22080173 [TBL] [Abstract][Full Text] [Related]
17. The safety and effectiveness of self-administration of intranasal live attenuated influenza vaccine in adults. Ambrose CS; Wu X Vaccine; 2013 Jan; 31(6):857-60. PubMed ID: 23261050 [TBL] [Abstract][Full Text] [Related]